Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort

Author(s): Jennifer Fusco*, Cassidy Henegar, Evelyn Byrd Quinlivan, Vani Vannappagari, Michael Aboud, Kimberly Smith, Gregory Fusco

Journal Name: Current HIV Research

Volume 17 , Issue 4 , 2019


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Women face unique complexities in HIV treatment yet are underrepresented in antiretroviral therapy (ART) studies.

Objective: This analysis assessed the one-year durability of the first integrase strand transfer inhibitor (INSTI)-based regimens prescribed to women in a large cohort of patients living with HIV in care.

Methods: Women with HIV who initiated their first INSTI-containing regimen between 08/12/2013 and 11/30/2015 were identified in the OPERA cohort, a collaboration of 79 US outpatient clinics. Discontinuation within the first year of treatment with an INSTI was compared between dolutegravir (DTG), raltegravir (RAL) and elvitegravir (EVG), using multivariable Cox regression and Kaplan- Meier estimates. Virologic response and regimen modifications were described and compared across INSTIs.

Results: A total of 537 treatment-naïve (DTG: 39%, EVG: 48%, RAL: 13%) and 878 treatmentexperienced (DTG: 57%, EVG: 29%, RAL: 13%) women were analyzed. In the first twelve months after initiation, women taking EVG or RAL were more likely to discontinue their initial INSTI than those taking DTG among both treatment-naïve (adjusted hazard ratio EVG vs. DTG: 1.59 (95% CI: 1.09, 2.39); RAL vs. DTG: 2.46 (1.49, 4.05)) and treatment-experienced women (EVG vs. DTG: 1.39 (1.02, 1.88); RAL vs. DTG: 2.17 (1.51, 3.12)). Following discontinuation of the initial INSTI, women commonly switched to a regimen containing a different drug from the INSTI class (treatment-naïve DTG: 34%, RAL: 33% EVG: 41%; treatment-experienced DTG: 23%, RAL: 19% EVG: 41%).

Conclusion: In treatment-naïve and treatment-experienced women living with HIV, women taking DTG had the lowest risk for early (≤1 year) discontinuation.

Keywords: Integrase inhibitors, discontinuation, treatment-naïve, treatment-experienced, HIV.

[1]
UNAIDS. UNAIDS report on the global AIDS epidemic 2010. [Available from. https://www.unaids.org/GlobalReport/doscuments/20101123_GlobalReport_full_en.pdf
[2]
Monforte Ad, Anderson J, Olczak A. What do we know about antiretroviral treatment of HIV in women? Antivir Ther (Lond) 2013; 18(Suppl. 2): 27-34.
[http://dx.doi.org/10.3851/IMP2647] [PMID: 23784804]
[3]
Umeh OC, Currier JS. Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin Drug Metab Toxicol 2006; 2(2): 273-83.
[http://dx.doi.org/10.1517/17425255.2.2.273] [PMID: 16866613]
[4]
Addo MM, Altfeld M. Sex-based differences in HIV type 1 pathogenesis. J Infect Dis 2014; 209(Suppl. 3): S86-92.
[http://dx.doi.org/10.1093/infdis/jiu175] [PMID: 24966195]
[5]
Short WR, Anderson JR. Caring for women with HIV: Unique needs and challenges. Cleve Clin J Med 2014; 81(11): 691-701.
[http://dx.doi.org/10.3949/ccjm.81a.14009] [PMID: 25368220]
[6]
Firnhaber C, Smeaton LM, Grinsztejn B, et al. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials 2015; 16(3): 89-99.
[http://dx.doi.org/10.1179/1528433614Z.0000000013] [PMID: 25979186]
[7]
Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet 2009; 374(9692): 796-806.
[http://dx.doi.org/10.1016/S0140-6736(09)60918-1] [PMID: 19647866]
[8]
Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr 2013; 63(1): 77-85.
[http://dx.doi.org/10.1097/QAI.0b013e31828ace69] [PMID: 23412015]
[9]
Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46(2): 125-33.
[http://dx.doi.org/10.1097/QAI.0b013e318157131c] [PMID: 17721395]
[10]
Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369(19): 1807-18.
[http://dx.doi.org/10.1056/NEJMoa1215541] [PMID: 24195548]
[11]
Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383(9936): 2222-31.
[http://dx.doi.org/10.1016/S0140-6736(14)60084-2] [PMID: 24698485]
[12]
Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: Final results of two randomised, placebo-controlled trials. Lancet Infect Dis 2013; 13(7): 587-96.
[http://dx.doi.org/10.1016/S1473-3099(13)70093-8] [PMID: 23664333]
[13]
Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2013; 13(11): 927-35.
[http://dx.doi.org/10.1016/S1473-3099(13)70257-3] [PMID: 24074642]
[14]
Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013; 382(9893): 700-8.
[http://dx.doi.org/10.1016/S0140-6736(13)61221-0] [PMID: 23830355]
[15]
Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 2014; 210(3): 354-62.
[http://dx.doi.org/10.1093/infdis/jiu051] [PMID: 24446523]
[16]
Akil B, Blick G, Hagins DP, et al. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study. Antivir Ther (Lond) 2015; 20(3): 343-8.
[http://dx.doi.org/10.3851/IMP2878] [PMID: 25321146]
[17]
Panel on Antiretroviral Guidelines for Adults and Adolescent. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. department of health and human services 2018. [Available from. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf
[18]
Centers for Disease Control and Prevention. HIV Among Women. 2019 [Available from. https://www.cdc.gov/hiv/group/gender/women/index.html
[19]
Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381(9868): 735-43.
[http://dx.doi.org/10.1016/S0140-6736(12)61853-4] [PMID: 23306000]
[20]
van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: Planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12(2): 111-8.
[http://dx.doi.org/10.1016/S1473-3099(11)70290-0] [PMID: 22018760]
[21]
Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013; 207(5): 740-8.
[http://dx.doi.org/10.1093/infdis/jis750] [PMID: 23225901]
[22]
DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379(9835): 2429-38.
[http://dx.doi.org/10.1016/S0140-6736(12)60918-0] [PMID: 22748590]
[23]
Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379(9835): 2439-48.
[http://dx.doi.org/10.1016/S0140-6736(12)60917-9] [PMID: 22748591]
[24]
Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015; 385(9987): 2606-15.
[http://dx.doi.org/10.1016/S0140-6736(15)60616-X] [PMID: 25890673]
[25]
Pozniak A, Markowitz M, Mills A, et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis 2014; 14(7): 590-9.
[http://dx.doi.org/10.1016/S1473-3099(14)70796-0] [PMID: 24908550]
[26]
Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: Randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012; 12(1): 27-35.
[http://dx.doi.org/10.1016/S1473-3099(11)70249-3] [PMID: 22015077]
[27]
Huhn GD, Tebas P, Gallant J, et al. A Randomized, open-label trial to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus darunavir in treatment-experienced HIV-1-infected adults. J Acquir Immune Defic Syndr 2017; 74(2): 193-200.
[http://dx.doi.org/10.1097/QAI.0000000000001193] [PMID: 27753684]
[28]
Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55(1): 39-48.
[http://dx.doi.org/10.1097/QAI.0b013e3181da1287] [PMID: 20404738]
[29]
Rockstroh JK, Lennox JL, Dejesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011; 53(8): 807-16.
[http://dx.doi.org/10.1093/cid/cir510] [PMID: 21921224]
[30]
Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet 2007; 369(9569): 1261-9.
[http://dx.doi.org/10.1016/S0140-6736(07)60597-2] [PMID: 17434401]
[31]
Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: Week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010; 50(4): 605-12.
[http://dx.doi.org/10.1086/650002] [PMID: 20085491]
[32]
Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: Results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49(9): 1441-9.
[http://dx.doi.org/10.1086/630210] [PMID: 19814627]
[33]
Davy-Mendez T, Eron JJ, Zakharova O, Wohl DA, Napravnik S. Increased persistence of initial treatment for hiv infection with modern antiretroviral therapy. J Acquir Immune Defic Syndr 2017; 76(2): 111-5.
[http://dx.doi.org/10.1097/QAI.0000000000001481] [PMID: 28628528]
[34]
Kowalska JD, Kubicka J, Siwak E, Pulik P, Firląg-Burkacka E, Horban A. Factors associated with the first antiretroviral therapy modification in older HIV-1 positive patients. AIDS Res Ther 2016; 13: 2.
[http://dx.doi.org/10.1186/s12981-015-0084-5] [PMID: 26744599]
[35]
Eaton EF, Tamhane AR, Burkholder GA, Willig JH, Saag MS, Mugavero MJ. Unanticipated effects of new drug availability on antiretroviral durability: Implications for comparative effectiveness research. Open Forum Infect Dis 2016; 3(2)ofw109
[http://dx.doi.org/10.1093/ofid/ofw109] [PMID: 27419181]
[36]
Raffi F, Esser S, Nunnari G, Pérez-Valero I, Waters L. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. HIV Med 2016; 17(Suppl. 5): 3-16.
[http://dx.doi.org/10.1111/hiv.12440] [PMID: 27714978]
[37]
Mesplède T, Quashie PK, Zanichelli V, Wainberg MA. Integrase strand transfer inhibitors in the management of HIV-positive individuals. Ann Med 2014; 46(3): 123-9.
[http://dx.doi.org/10.3109/07853890.2014.883169] [PMID: 24579911]
[38]
Gianotti N, Lorenzini P, Cozzi-Lepri A, et al. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. J Antimicrob Chemother 2019; 74(9): 2732-41.
[http://dx.doi.org/10.1093/jac/dkz237] [PMID: 31173639]
[39]
Peñafiel J, de Lazzari E, Padilla M, et al. Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother 2017; 72(6): 1752-9.
[http://dx.doi.org/10.1093/jac/dkx053] [PMID: 28333231]
[40]
Elzi L, Erb S, Furrer H, et al. Adverse events of raltegravir and dolutegravir. AIDS 2017; 31(13): 1853-8.
[http://dx.doi.org/10.1097/QAD.0000000000001590] [PMID: 28692533]
[41]
De La Mata NL, Cooper DA, Russell D, et al. Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: An Australian cohort study. Sex Health 2016; 13(4): 335-44.
[http://dx.doi.org/10.1071/SH15210] [PMID: 27097796]
[42]
Barber TJ, Geretti AM, Anderson J, et al. Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antivir Ther (Lond) 2011; 16(6): 805-14.
[http://dx.doi.org/10.3851/IMP1818] [PMID: 21900712]
[43]
Eaton EF, Tamhane A, Davy-Mendez T, et al. Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure. AIDS 2018; 32(3): 347-55.
[PMID: 29194118]
[44]
Di Biagio A, Cozzi-Lepri A, Prinapori R, et al. Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy. J Acquir Immune Defic Syndr 2016; 71(3): 263-71.
[http://dx.doi.org/10.1097/QAI.0000000000000849] [PMID: 26871881]
[45]
Raffi F, Yazdanpanah Y, Fagnani F, Laurendeau C, Lafuma A, Gourmelen J. Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database. J Antimicrob Chemother 2015; 70(7): 2121-8.
[http://dx.doi.org/10.1093/jac/dkv083] [PMID: 25904729]
[46]
Häggblom A, Lindbäck S, Gisslén M, et al. HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014. PLoS One 2017; 12(2)e0171227
[http://dx.doi.org/10.1371/journal.pone.0171227] [PMID: 28207816]
[47]
McKinnell JA, Willig JH, Westfall AO, et al. Antiretroviral prescribing patterns in treatment-naïve patients in the United States. AIDS Patient Care STDS 2010; 24(2): 79-85.
[http://dx.doi.org/10.1089/apc.2009.0220] [PMID: 20059309]
[48]
Wong E, Trustman N, Yalong A. HIV pharmacotherapy: A review of integrase inhibitors. JAAPA 2016; 29(2): 36-40.
[http://dx.doi.org/10.1097/01.JAA.0000475465.07971.19] [PMID: 26818644]
[49]
Astuti N, Maggiolo F. Single-Tablet Regimens in HIV Therapy. Infect Dis Ther 2014; 3(1): 1-17.
[http://dx.doi.org/10.1007/s40121-014-0024-z] [PMID: 25134808]
[50]
Kandel CE, Walmsley SL. Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Des Devel Ther 2015; 9: 3547-55.
[http://dx.doi.org/10.2147/DDDT.S84850] [PMID: 26185421]
[51]
Di Biagio A, Lorenzini P, Gustinetti G, et al. Durability of second antiretroviral regimens in the italian cohort naive antiretrovirals foundation study and factors associated with discontinuation. AIDS Patient Care STDS 2017; 31(12): 487-94.
[http://dx.doi.org/10.1089/apc.2017.0140] [PMID: 29211512]
[52]
Clumeck N, Molina JM, Henry K, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 2014; 65(3): e121-4.
[http://dx.doi.org/10.1097/QAI.0000000000000089] [PMID: 24346640]
[53]
Gallant J, Brunetta J, Crofoot G, et al. Brief report: Efficacy and safety of switching to a single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-1/Hepatitis B-Coinfected adults. J Acquir Immune Defic Syndr 2016; 73(3): 294-8.
[http://dx.doi.org/10.1097/QAI.0000000000001069] [PMID: 27171740]
[54]
Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 2010; 24(18): 2835-40.
[http://dx.doi.org/10.1097/QAD.0b013e328340a209] [PMID: 21045636]
[55]
Hanna DB, Hessol NA, Golub ET, et al. Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. J Acquir Immune Defic Syndr 2014; 65(5): 587-96.
[http://dx.doi.org/10.1097/QAI.0000000000000082] [PMID: 24326606]
[56]
Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010; 4: 115-25.
[PMID: 20517472]
[57]
Sterrantino G, Santoro L, Bartolozzi D, Trotta M, Zaccarelli M. Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era. Patient Prefer Adherence 2012; 6: 427-33.
[http://dx.doi.org/10.2147/PPA.S31385] [PMID: 22723727]
[58]
Pozniak A, Arribas JR, Gathe J, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr 2016; 71(5): 530-7.
[http://dx.doi.org/10.1097/QAI.0000000000000908] [PMID: 26627107]
[59]
Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr 2014; 67(1): 52-8.
[http://dx.doi.org/10.1097/QAI.0000000000000225] [PMID: 24872136]
[60]
Mills A, Crofoot G Jr, McDonald C, et al. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study. J Acquir Immune Defic Syndr 2015; 69(4): 439-45.
[http://dx.doi.org/10.1097/QAI.0000000000000618] [PMID: 25867913]
[61]
Pozniak A, Flamm J, Antinori A, et al. Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. HIV Clin Trials 2017; 18(4): 141-8.
[http://dx.doi.org/10.1080/15284336.2017.1338844] [PMID: 28689453]
[62]
Bollen P, Reiss P, Schapiro J, Burger D. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection. Expert Opin Drug Saf 2015; 14(9): 1457-72.
[http://dx.doi.org/10.1517/14740338.2015.1059818] [PMID: 26134478]
[63]
Bhatti AB, Usman M, Kandi V. Current scenario of HIV/AIDS, treatment options, and major challenges with compliance to antiretroviral therapy. Cureus 2016; 8(3)e515
[http://dx.doi.org/10.7759%2Fcureus.515] [PMID: 27054050]
[64]
Jiang J, Xu X, Guo W, et al. Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: A meta-analysis of randomized controlled trials. AIDS Res Ther 2016; 13(1): 30.
[http://dx.doi.org/10.1186/s12981-016-0115-x] [PMID: 27617024]
[65]
Lepik KJ, Yip B, Ulloa AC, et al. Adverse drug reactions to integrase strand transfer inhibitors. AIDS 2018; 32(7): 903-12.
[http://dx.doi.org/10.1097/QAD.0000000000001781] [PMID: 29424784]
[66]
Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med 2017; 18(1): 56-63.
[http://dx.doi.org/10.1111/hiv.12468] [PMID: 27860104]
[67]
Hughes CA, Tseng A, Cooper R. Managing drug interactions in HIV-infected adults with comorbid illness. CMAJ 2015; 187(1): 36-43.
[http://dx.doi.org/10.1503/cmaj.131626] [PMID: 25225224]
[68]
Krentz HB, Gill MJ. The impact of non-antiretroviral polypharmacy on the continuity of antiretroviral therapy (ART) among HIV patients. AIDS Patient Care STDS 2016; 30(1): 11-7.
[http://dx.doi.org/10.1089/apc.2015.0199] [PMID: 26544766]
[69]
Jakeman B, Nasiri M, Ruth L, Morse C, Mahatme S, Patel N. Comparing the frequencies of contraindicated drug-drug interactions between differing antiretroviral regimens in HIV-infected patients. Ann Pharmacother 2017; 51(5): 365-72.
[http://dx.doi.org/10.1177/1060028016685115] [PMID: 28367698]
[70]
Justice AC, Gordon KS, Skanderson M, et al. Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. AIDS 2018; 32(6): 739-49.
[http://dx.doi.org/10.1097/QAD.0000000000001756] [PMID: 29543653]
[71]
Baecke C, Gyssens IC, Decoutere L, van der Hilst JCH, Messiaen P. Prevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical study. Neth J Med 2017; 75(6): 235-40.
[PMID: 28741582]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 4
Year: 2019
Published on: 07 November, 2019
Page: [266 - 276]
Pages: 11
DOI: 10.2174/1570162X17666190927161537
Price: $65

Article Metrics

PDF: 23
HTML: 4